论文部分内容阅读
目的 :评价新一代氟喹诺酮类抗菌药物莫西沙星片剂治疗下呼吸道感染的疗效与安全性。方法 :莫西沙星片与左旋氧氟沙星片随机对照治疗下呼吸道感染共 6 4例 ,莫西沙星组 33例 (男性 13例 ,女性 2 0例 ,年龄 6 0 .9± 10 .6 8) ,左旋氧氟沙星组 31例 (男性 13例 ,女性 18例 ,年龄 5 6 .0± 13.5 5 )。剂量均为 4 0 0mg ,po ,qd和 2 0 0mg ,po ,bid ;疗程均为 7～ 14天。结果 :莫西沙星和左旋氧氟沙星治疗下呼吸道感染的有效率分别为 6 6 .7%和 5 8.1% ,细菌清除率均为 10 0 % ,不良反应发生率分别为 5 .5 6 %和 11.1% ,2组比较均无显著性差异 ,P >0 .0 5。结论 :莫西沙星片剂治疗下呼吸道感染疗效确切 ,安全性好。
Objective: To evaluate the efficacy and safety of a new generation fluoroquinolone antibiotic moxifloxacin tablet in the treatment of lower respiratory tract infection. Methods: A total of 64 cases of lower respiratory tract infection were randomly assigned to moxifloxacin tablets and levofloxacin tablets, 33 cases were moxifloxacin group (13 males and 20 females, age 60.9 ± 10.68 ), Levofloxacin group of 31 patients (13 males and 18 females, age 56.06 ± 13.5 5). The dosage was 400 mg, po, qd and 200 mg, po, bid respectively; all the courses were 7 to 14 days. Results: The effective rates of moxifloxacin and levofloxacin in the treatment of lower respiratory tract infections were 66.7% and 5.11% respectively, the bacterial clearance rate was 100% and the adverse reaction rates were respectively 5.66% And 11.1% respectively. There was no significant difference between the two groups (P> 0.05). Conclusion: Moxifloxacin tablets in the treatment of lower respiratory tract infection is effective and safe.